June 25, 2020



Utilize our networking app to schedule one-to-one online meetings. Learn more.


Using AI in Drug Discovery

This panel will explore emerging technologies, examine machine learning and data in drug research, and uncover how they work in combination to support medical breakthroughs. Uncover how to make it from the discovery stage to trials, while speeding up the process in drug development.

Charles Fisher – CEO & Founder, Unlearn.AI
Abraham Heifets – CEO & Co-founder, Atomwise
Teresa Lavoie – Principal, Fish & Richardson
Jeffrey Lu – CEO & Co-founder, Engine Biosciences


Pure Tech & Pure Science: Building on San Francisco’s Tech Identity to Further Life Sciences and Healthcare

In this session, we’ll discuss tech merging with community health, and the importance of efficiency and risk mitigation. Panelists will dissect some of the intricacies of understanding regulatory expectations and how to approach the dilemma of technology outpacing regulations. How can you submit without delays, and has the pathway to approval changed since January 2020? Will data sharing accelerate approvals and what are the ramifications?


What’s Next: Investment, Partnerships & Pushing Life Sciences Forward

San Francisco holds a significant amount of capital – but where are there gaps in the market? How are investor, entrepreneur, and partnerships formed, and how can you get an investor to follow your work from the beginning? With the talent in the Bay Area, what does the future hold for bringing more therapies to market? And as the COVID-19 pandemic continues, what role will the life sciences tech landscape look like? Does it change investment models, speed up drugs to market, or create competition?

Mary Rozenman – CFO/CBO, insitro
Sami Inkinen – CEO & Co-founder, Virta Health
Andrew Radin – CEO & Co-founder, twoXAR
Michael Henderson – CBO, BridgeBio



Utilize our networking app to schedule one-to-one online meetings. Learn more.